Centessa Pharmaceuticals
Update in progressCNTA (NGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Centessa Pharmaceuticals is a clinical-stage company that discovers, develops, and delivers medicines. Its lead program, ORX750, is an orally delivered OX2R agonist in Phase 2a for idiopathic hypersomnia and narcolepsy types 1 and 2. It also develops ORX142 for neurological and neurodegenerative disorders with symptoms such as daytime sleepiness and cognitive deficits, and ORX489 for neuropsychiatric disorders. LockBody directs effector activity into tumors. Founded 2020, based in Altrincham, UK.
Company score
- Sentiment
- 0.11
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.02
- Governance
- 0.26
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.08
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNGM
- LocationUnited Kingdom
- CEODr. Mario Alberto Accardi Ph.D.
- Founded2020
- Employees129
- Websitecentessa.com
Identifiers
- ISINUS1523091007
- FIGIBBG01081FC59
- CUSIP152309100
- CIK0001847903